Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model

J Am Coll Cardiol. 2010 Feb 23;55(8):801-9. doi: 10.1016/j.jacc.2009.10.033.

Abstract

Objectives: This study investigated whether ranolazine reduces dofetilide-induced torsades de pointes (TdP) in a model of long QT syndrome with down-regulated K(+) currents due to hypertrophic remodeling in the dog with chronic atrioventricular block (cAVB).

Background: Ranolazine inhibits the late Na(+) current (I(NaL)) and is effective against arrhythmias in long QT3 syndromes despite its blocking properties of the rapid component of delayed rectifying potassium current.

Methods: Ranolazine was administered to cAVB dogs before or after TdP induction with dofetilide and electrophysiological parameters were determined including beat-to-beat variability of repolarization (BVR). In single ventricular myocytes, effects of ranolazine were studied on I(NaL), action potential duration, and dofetilide-induced BVR and early afterdepolarizations.

Results: After dofetilide, ranolazine reduced the number of TdP episodes from 10 +/- 3 to 3 +/- 1 (p < 0.05) and partially reversed the increase of BVR with no abbreviation of the dofetilide-induced QT prolongation. Likewise, pre-treatment with ranolazine, or using lidocaine as a specific Na(+) channel blocker, attenuated TdP, but failed to prevent dofetilide-induced increases in QT, BVR, and ectopic activity. In cAVB myocytes, ranolazine suppressed dofetilide-induced early afterdepolarizations in 25% of cells at 5 micromol/l, in 75% at 10 micromol/l, and in 100% at 15 micromol/l. At 5 micromol/l, ranolazine blocked 26 +/- 3% of tetrodotoxin-sensitive I(NaL), and 49 +/- 3% at 15 micromol/l. Despite a 54% reduction of I(NaL) amplitude in cAVB compared with control cells, I(NaL) inhibition by 5 micromol/l tetrodotoxin equally shortened relative action potential duration and completely abolished dofetilide-induced early afterdepolarizations.

Conclusions: Despite down-regulation of I(NaL) in remodeled cAVB hearts, ranolazine is antiarrhythmic against drug-induced TdP. The antiarrhythmic effects are reflected in concomitant changes of BVR.

Publication types

  • Comparative Study

MeSH terms

  • Acetanilides / pharmacology*
  • Animals
  • Anti-Arrhythmia Agents / pharmacology*
  • Atrioventricular Block / complications
  • Dogs
  • Lidocaine / pharmacology
  • Models, Animal
  • Phenethylamines / pharmacology
  • Piperazines / pharmacology*
  • Potassium Channel Blockers / pharmacology
  • Ranolazine
  • Sodium Channels / drug effects*
  • Sulfonamides / pharmacology
  • Torsades de Pointes / chemically induced
  • Torsades de Pointes / drug therapy*

Substances

  • Acetanilides
  • Anti-Arrhythmia Agents
  • Phenethylamines
  • Piperazines
  • Potassium Channel Blockers
  • Sodium Channels
  • Sulfonamides
  • Lidocaine
  • Ranolazine
  • dofetilide